The largest provider of human tetanus antitoxin (TAT) in China, JIANGXI BIO, has officially launched the global offering for its Hong Kong stock exchange listing. The company, with a dominant 65.8% domestic market share and the unique label of a "full-industry-chain antiserum platform," has attracted some market attention. However, beneath this narrative of an industry leader, several core risks—including extreme product concentration, tightening raw material supply, new VAT policies impacting profits, a weak cornerstone investor base, and family control—introduce multiple uncertainties into this IPO.

Historical Growth Meets Future Headwinds

From 2023 to 2025, the company's operating revenue grew steadily from RMB 198 million to RMB 221 million and then to RMB 235 million. Over the same period, net profit attributable to the parent company rose from RMB 55.48 million to RMB 94.79 million, representing a compound growth rate exceeding 30%. This profit improvement was primarily driven by domestic centralized procurement price increases for human TAT and expanded overseas exports. The comprehensive gross profit margin climbed from 67.8% to 76.8% over the three years, as scale effects and process optimizations continued to release profit potential.

However, a significant business weakness is glaringly apparent. During the reporting period, revenue from human TAT accounted for 93.0%, 93.3%, and 96.4% of total revenue, respectively. Revenue from other sources, such as veterinary drug sales and technical services, combined for less than 7%, indicating extremely weak business resilience. Any changes in centralized procurement policies, the international trade environment, or competitor supply could directly and severely impact the company's revenue.

Starting from January 2026, the VAT rate for human TAT will increase from 3% to 13%. With the terminal selling price fixed under the domestic Volume-Based Procurement (VBP) scheme, the additional tax burden must be shared between the company and distributors, forcing the company to lower its supply price to distributors and directly compressing its gross margin space. Compounded by factors such as rising R&D expenses as pipelines like antivenom serum enter clinical trials, increased sales expenses for commercializing veterinary drugs, and a temporary weakening in overseas exports in the first half of the year, the company explicitly warns in its prospectus that its full-year 2026 net profit will show a significant decline compared to 2025, breaking its short-term growth narrative.

Clear Leadership but Limited Growth Potential

Based on 2025 sales volume, the company holds a 65.8% share of the domestic human TAT market and a 45.8% share globally, maintaining over half of the domestic market share for 19 consecutive years. Its products are exported to over 30 countries in Asia and Africa, accounting for nearly 100% of China's similar product exports. The company has also established a full-industry-chain platform encompassing horse breeding, plasma collection, antibody purification, and preparation production, creating very high barriers to entry.

However, growth potential in this niche segment is limited. The domestic market for passive tetanus immunization is nearing saturation, with incremental growth relying solely on expansion into low-income countries overseas. Pipelines for antivenom and rabies serum are still in early clinical stages and are not expected to contribute revenue until 2027 at the earliest. In the long term, there is a risk of product substitution by monoclonal antibody preparations. If competitors expand production and engage in low-price competition, the gross margin on overseas exports will remain under sustained pressure.

Substantial Dividends and Governance Concerns

The company is a typical second-generation family-run business. The controlling shareholder, Jing Yue, holds a combined 76.64% stake pre-IPO through two holding platforms, Hainan Zhizheng and Qianhai Tianzheng. Even after the global offering, she will retain 67.63% of the voting rights, possessing absolute veto power, which severely dilutes the voice of minority shareholders.

Most shareholders in the equity structure are relatives of the controlling shareholder, affiliated enterprises, or employee shareholding platforms. Her sister, Jing Ruihua, serves as an executive director and joint company secretary but lacks the qualifications required by the Hong Kong Stock Exchange for a compliance secretary. The controlling persons of shareholding entities like Aohai Industrial, Hanyi Culture, and Tianshun Industrial are Jing Yue's parents and relatives, with multiple pre-IPO equity transfers occurring within the family. Historically, the company had multi-layered shareholding arrangements, which, although fully rectified, were a key focus of inquiries from the China Securities Regulatory Commission regarding the overseas listing, raising questions about the standardization of its equity evolution.

Furthermore, the company conducted three substantial cash dividends in 2023 and 2024: a RMB 10 million dividend in May 2023, a RMB 76.20 million dividend in October 2023, and a RMB 40.80 million dividend in September 2024, totaling RMB 127 million over three years.

Compared to the adjusted net profit of only RMB 134 million for 2023 and 2024 combined, the dividend payout ratio exceeded 90%, effectively distributing nearly all operating results from those two years to shareholders. Based on the pre-IPO 76.64% shareholding, the controlling shareholder's family system alone would have received approximately RMB 97 million in dividends.

Weak Cornerstone Investor Support

The cornerstone investment portion of this IPO is another focal point of market skepticism. The company has introduced only one cornerstone investor—Wise Strategy Holdings Limited (WSH)—with a total subscription amount of HKD 50 million, representing just 10.56% to 14.79% of the global offering shares (depending on the final offer price). This cornerstone proportion is notably low for recent Hong Kong IPOs. Especially in the current market environment, the dominance of a single, non-prominent long-term institution fails to provide strong market endorsement.